Fabry Disease Clinical Trials

Find Fabry Disease Clinical Trials Near You

Anderson-Fabry Disease Fitness Improvement Training: A-FAD-FIT

Status: Recruiting
Intervention Type: Behavioral
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

This study will evaluate physical function, cardiorespiratory fitness, muscle strength, and quality of life in patients with Fabry disease and assess the effects of a 12-week physiotherapy-led exercise programme. Participants will be non-randomly assigned to an exercise intervention group or a control group receiving no study-specific exercise intervention. The intervention group will be assessed at baseline, immediately after the 12-week intervention, and 12 months after baseline. The control group will be assessed at baseline and 12 months after baseline.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Confirmed diagnosis of Fabry disease

• Age 18 years or older

• Followed at a participating clinical center

• Able to understand the study procedures and provide informed consent

• Clinically stable and medically suitable for exercise testing and participation in the exercise programme

Contact Information
Primary
Jan Vávra, Masters
Jan.Vavra2@vfn.cz
+420601200272
Time Frame
Start Date: 2025-10-06
Estimated Completion Date: 2028-12-31
Participants
Target number of participants: 50
Treatments
Experimental: Exercise Intervention Group
Participants will complete a 12-week physiotherapy-led exercise programme consisting of one supervised exercise session per week and two home-based exercise sessions per week, together with a progressive increase in daily step count. Supervised sessions include a brief aerobic warm-up followed by strengthening exercises using body weight and resistance bands. Participants will be assessed at baseline, immediately after the 12-week intervention, and 12 months after baseline.
No_intervention: Control Group
Participants will receive no study-specific exercise intervention. They will be assessed at baseline and 12 months after baseline.
Related Therapeutic Areas
Sponsors
Leads: General University Hospital, Prague

This content was sourced from clinicaltrials.gov